 LA JOLLA, Calif., June 21, 2021 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that positive results from a Phase 2 trial of MN-166 ibudilast in alcohol use disorder AUD were published in Natures Translational Psychiatry. 